Comment on “A pragmatic trial evaluating the impact of the anumana clinical decision support tool for guideline-directed management of heart failure (ACT-HF): Clinical trial design and methods”
Bingjun Che, Lijiang Li · 2026
Read Comment on “A pragmatic trial evaluating the impact of the anumana clinical decision support tool for guideline-directed management of heart failure (ACT-HF): Clinical trial design and methods” by Bingjun Che, Lijiang Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13631519.txt.
Description
Bingjun Che and Lijiang Li comment on the design of a heart failure trial, in this 2026 letter. The trial tests a software tool that prompts doctors to prescribe the full set of guideline-backed drugs for heart failure. Its main measure is a simple count of how many drug classes each patient is prescribed after ninety days. Che and Li argue that the count alone can mislead.
A prescription counted at ninety days might be at a dose too low to help, or stopped weeks earlier because the patient could not tolerate it. Past registry data link lower death rates to reaching target doses, not merely to starting more drug classes. The letter urges the trial team to record dose levels and whether patients stayed on each drug. Without that detail, a positive result could hide weak or short-lived treatment.
Catalog record
| CREATOR | Bingjun Che, Lijiang Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |